

- (51) International Patent Classification:
C07K 16/28 (2006.01) C12N 15/113 (2010.01)
- (21) International Application Number:
PCT/EP2015/072644
- (22) International Filing Date:
30 September 2015 (30.09.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/058,254 1 October 2014 (01.10.2014) US
- (71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building Granta Park, Cambridge, Cambridgeshire CB21 6GH (GB).
- (72) Inventors: **BUCHANAN, Andrew**; MedImmune Limited Milstein Building, Cambridge, Cambridgeshire, Granta Park (GB). **CHODORGE, Matthieu**; MedImmune Limited Milstein Building, Cambridge, Cambridgeshire, Granta Park (GB). **CARIUK, Peter**; MedImmune Limited Milstein Building, Cambridge, Cambridgeshire, Granta Park (GB). **HUSMARK, Johanna**; AstraZeneca Intellectual Property, AstraZeneca Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **BALENDRAN, Clare**; AstraZeneca, 431 83 Molndal (SE). **PANDEY, Deepesh**; The Johns Hopkins University, 3400 N. Charles Street, Bal-

timore, MD 21218 (US). **CHANG, Fumin**; The Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218 (US). **BERKOWITZ, Daniel**; The Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218 (US). **ROMER, Lewis**; The Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218 (US).

- (74) Agent: **TTOFI, Evangelia**; Milstein Building Granta Park, Cambridge, Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: BINDING PROTEINS SPECIFIC FOR LOX1 AND USES THEREOF




Figure 1A




Figure 1C




Figure 1B




Figure 1D

(57) Abstract: This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*